news
Researchers discover how C. difficile toxins enter the interiors of cells
9 June 2015 | By Victoria White
Researchers have identified the molecular docking site that is responsible for C. difficile toxins being able to bind to a receptor...
List view / Grid view
Antibiotics
Antibiotics are a type of antimicrobial drug used in the treatment and prevention of bacterial infections.
news
Auspherix raises £6 million to progress novel antibiotics and establishes UK operations
3 June 2015 | By Victoria White
Auspherix has raised £6 million in a Series A venture financing and is establishing operations on the Stevenage Bioscience Catalyst site...
news
MGB Biopharma succeeds in developing an IV formulation of MGB-BP-3 for the treatment of hospital-acquired infections
2 June 2015 | By Victoria White
MGB Biopharma has developed a stable IV formulation of MGB-BP-3 for the treatment of Gram-positive hospital-acquired infections...
news
Re-engineered spectinomycin shows potential for treatment of drug-resistant bacteria
21 May 2015 | By Victoria White
Researchers have developed a second-generation of spectinomycin that shows early effectiveness against common bacterial infections...
news
Scientists discover why Streptococcus pneumoniae infections can cause fatal heart complications
19 May 2015 | By Victoria White
Researchers have discovered a key cause of life threatening heart complications, conditions that frequently follow severe Streptococcus pneumoniae infection..
news
Antibiotic Research UK welcomes the O’Neill Commission’s recommendation to create $2b global fund to tackle antibiotic resistance
14 May 2015 | By Victoria White
Antibiotic Research UK has welcomed this latest report to come from Jim O’Neill's Review on Antimicrobial Resistance and has endorses its recommendations...
news
Preclinical data from novel SYN-005 programme for the treatment of Pertussis presented at ECCMID 2015
27 April 2015 | By Victoria White
Preclinical data from Synthetic Biologics’ novel SYN-005 programme for the treatment of Pertussis were presented in two posters at ECCMID 2015...
news
Ferring and the Institut Pasteur collaborate in novel IDB drug development project
16 April 2015 | By Victoria White
Ferring and Institut Pasteur are collaborating aimed at identifying and developing bacteriophages to treat patients with inflammatory bowel disease (IDB)...
news
Nabriva Therapeutics announces financing to advance clinical development of new class of antibiotics
7 April 2015 | By Victoria White
Nabriva, a biotechnology company focused on developing pleuromutilins, has announced the successful completion of a $120 million Series B financing...
news
Phico Therapeutics receives Translation Award to advance its SASPject™ PT4 aimed at Escherichia coli and Klebsiella pneumoniae towards clinical trials
9 March 2015 | By Phico Therapeutics
Phico Therapeutics, a biotechnology company developing a novel platform technology for a new generation of antibiotics aimed at overcoming antibacterial resistance, has been awarded a £2.25M Translation Award by the Wellcome Trust to develop its SASPject™ PT4 antibiotic, aimed at Escherichia coli and Klebsiella pneumoniae...
news
Motif Bio announces intention to float on AIM
3 February 2015 | By Motif Bio
Motif Bio plc is seeking to raise at least £4 million through a placing of new ordinary shares and admission to trading on AIM...
news
First patient enrolled in the New Drugs 4 Bad Bugs (ND4BB) programme
3 February 2015 | By Innovative Medicines Initiative (IMI)
Two years after the start of the Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) programme, the first patient has been enrolled into a Phase 2 trial sponsored by MedImmune, the global biologics research and development arm of AstraZeneca. The trial with MEDI4893 is among mechanically ventilated intubated…
news
Roche, Meiji and Fedora join forces to tackle increasing bacterial resistance to antibiotics
13 January 2015 | By Roche
Roche, Meiji Seika Pharma (Meiji) and Fedora announced that they have entered into a license agreement for the development and commercialization of OP0595, a beta-lactamase inhibitor in phase I clinical development...
news
Scientists discover bacteria’s clever defence mechanism
19 November 2014 | By Diamond
Structure of EzrA protein could help identify new antibiotic targets...
news
Auspherix and Domainex announce collaboration to develop new drugs to treat antibiotic-resistant bacterial infections
15 October 2014 | By Domainex
Domainex Ltd. and Auspherix Pty Ltd announced a collaboration that will progress Auspherix’s novel anti-infective drug discovery programme towards the nomination of a clinical candidate...
